ADVENTRX Reports Phase II CoFactor Trial Update
6th Oct 2005, 15:33 GMT
ADVENTRX Pharmaceuticals announced that patient follow up is nearly complete and data are being analyzed in its US-based Phase II COFU trial.
ADVENTRX Reports Phase II CoFactor Trial Update related news:
- Lumen Therapeutics Announces Completion of the Phase I Trial and Phase II Development Plans for Lt-1951 - a Potential Treatment for Prevention of Coronary Artery Bypass Graft Failure — Surgery News from StratCenter.com
- ADVENTRX Acquires Additional Oncology Drug Through Exclusive License Agreement — FDA News News from StratCenter.com
- Patient Enrollment Temporarily Suspended in Investigational Clinical Trial of REOPRO(R) (abciximab) for Acute Ischemic Stroke — Hispanic Business Magazine
- Viventia receives Health Canada clearance to initiate Phase II cancer trial for Proxinium — FDA News News from StratCenter.com
- FDA approves trial of Forbes Medi-Tech cholesterol drug — Pharmaceutical Business Review Online
- Patient Enrollment Temporarily Suspended in Investigational Clinical Trial of REOPRO for Acute Ischemic Stroke — Pharmaceuticals News from StratCenter.com
- Market Pulse: Endo Pharma reports positive Phase III Oxymorphone trial — Pharmaceuticals News from StratCenter.com
- Health Stocks in Motion — TheStreet.com
- STAR launches Phase II of "Music in the Park" Series — Bollywood News
- Synthetic Blood to Accelerate Phase II Clinical Development of Oxycyte — Financial News News from StratCenter.com
Latest news from Pharmaceuticals News from StratCenter.com:
- Spectrum Pharmaceuticals to Receive $5 mln Milestone Payment From PAR Pharmaceutical for Sumatriptan Injection
- Medco to Present at the Credit Suisse Annual Healthcare Conference
- Bob Dole Medicare Podcast Helps Seniors through 2007 Drug Coverage Enrollment Process
- Unique Sugar Improves Energy, Pain and Quality of Life in Fibromyalgia and Chronic Fatigue Patients!
- Care Clinic Purchases Pinnacle Easy Care
- Pegasystems Enhances 2 Business Critical BPM Frameworks for the Healthcare Industry
- Isis Cholesterol Drug Shown Effective
- Taro Receives Marketing Authorization in UK for Etopan XL Tablets 600 mg, Etodolac
- Nymox Reports Q3 2006 Financial Results
- RemoteMDx Raises $6 mln in Private Placement